By Business/Source
Currency:USD
2026/Q1
Stock NameRevenueRatio
Discovery, development, manufacturing and commercialization of RNA interference (RNAi) therapeutics264.03M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States829.45M100.00%